



myeloid leukemia, T cell lymphoma, T cell non-Hodgkin lymphoma, chronic myeloid leukemia, chronic lymphoid leukemia, and multiple myeloma.

The claims presented above incorporate changes as indicated by the marked-up versions below.

12. (Amended) The composition of claim 11, wherein said activated lymphoid cells are lymphoid tumor cells representing a disease selected from B cell non-Hodgkin lymphoma, B cell lymphoma, B cell acute lymphoid leukemia, Burkitt lymphoma, Hodgkin lymphoma, hairy cell leukemia, acute myeloid leukemia, T cell lymphoma, T cell non-Hodgkin lymphoma, chronic myeloid leukemia, chronic lymphoid leukemia, and multiple myeloma ~~myeloid leukemia~~.
51. (Amended) The use according claim 49 or 50, wherein said treatment is the treatment of a disorder selected from B cell non-Hodgkin lymphoma, B cell lymphoma, B cell acute lymphoid leukemia, Burkitt lymphoma, Hodgkin lymphoma, hairy cell leukemia, acute myeloid leukemia, T cell lymphoma, T cell non-Hodgkin lymphoma, chronic myeloid leukemia, chronic lymphoid leukemia, and multiple myeloma ~~myeloid leukemia~~.

REMARKS

In reply to the outstanding Restriction Requirement, mailed October 15, 2002, in connection with the above application, Applicants hereby elect Group I (claims 1-38, 43, 55, 56, 59-63, 66-95, and 109-115) with traverse. The period for reply has been extended to December 14, 2002, by the accompanying petition for a one month extension.

The Office Action alleges that Group I and Group II claims are directed to structurally and functionally different products made by different methods and have different uses. Applicants submit that Group II claims are directed to nucleic acids encoding the polypeptides of the Group I claims. A search of the subject matter of the Group I claims would necessarily entail the search of the subject matter of the Group II claims. Therefore, contrary to the Office Action's assertion, simultaneous examination of both these Groups would not constitute undue burden for the Examiner, and would make efficient use of the Patent Office resources.